Coya Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 7.99 million compared to USD 12.24 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 4.73 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.97 USD | -1.32% |
|
-0.33% | -19.43% |
Jul. 01 | Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell Microcap Value Index | CI |
Jul. 01 | Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell 3000E Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.43% | 90.87M | |
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- COYA Stock
- News Coya Therapeutics, Inc.
- Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023